PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000851172.77306.8c |
| _version_ | 1797281276155133952 |
|---|---|
| author | G. U. Naylor S. Mant C. Bedford D. Turner M. Furtado D. Lewis |
| author_facet | G. U. Naylor S. Mant C. Bedford D. Turner M. Furtado D. Lewis |
| author_sort | G. U. Naylor |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:55:14Z |
| format | Article |
| id | doaj.art-b4495620fdbf4a1f966637b05bb36a4b |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:55:14Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-b4495620fdbf4a1f966637b05bb36a4b2024-03-03T04:28:45ZengWileyHemaSphere2572-92412022-06-0161956195710.1097/01.HS9.0000851172.77306.8c202206003-01956PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.G. U. Naylor0S. Mant1C. Bedford2D. Turner3M. Furtado4D. Lewis51 Haematology, University Hospitals Plymouth NHS trust, Plymouth1 Haematology, University Hospitals Plymouth NHS trust, Plymouth2 Haematology, Royal Cornwall Hospitals NHS Trust, Truro3 Haematology, Torbay and South Devon Hospitals NHS Trust, Torbay, United Kingdom2 Haematology, Royal Cornwall Hospitals NHS Trust, Truro1 Haematology, University Hospitals Plymouth NHS trust, Plymouthhttp://journals.lww.com/10.1097/01.HS9.0000851172.77306.8c |
| spellingShingle | G. U. Naylor S. Mant C. Bedford D. Turner M. Furtado D. Lewis PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES. HemaSphere |
| title | PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES. |
| title_full | PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES. |
| title_fullStr | PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES. |
| title_full_unstemmed | PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES. |
| title_short | PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES. |
| title_sort | pb2085 upfront treatment of mantle cell lymphoma mcl with r hdac rituximab high dose cytarabine dexamethasone in young high risk patients is well tolerated and leads to durable responses |
| url | http://journals.lww.com/10.1097/01.HS9.0000851172.77306.8c |
| work_keys_str_mv | AT gunaylor pb2085upfronttreatmentofmantlecelllymphomamclwithrhdacrituximabhighdosecytarabinedexamethasoneinyounghighriskpatientsiswelltoleratedandleadstodurableresponses AT smant pb2085upfronttreatmentofmantlecelllymphomamclwithrhdacrituximabhighdosecytarabinedexamethasoneinyounghighriskpatientsiswelltoleratedandleadstodurableresponses AT cbedford pb2085upfronttreatmentofmantlecelllymphomamclwithrhdacrituximabhighdosecytarabinedexamethasoneinyounghighriskpatientsiswelltoleratedandleadstodurableresponses AT dturner pb2085upfronttreatmentofmantlecelllymphomamclwithrhdacrituximabhighdosecytarabinedexamethasoneinyounghighriskpatientsiswelltoleratedandleadstodurableresponses AT mfurtado pb2085upfronttreatmentofmantlecelllymphomamclwithrhdacrituximabhighdosecytarabinedexamethasoneinyounghighriskpatientsiswelltoleratedandleadstodurableresponses AT dlewis pb2085upfronttreatmentofmantlecelllymphomamclwithrhdacrituximabhighdosecytarabinedexamethasoneinyounghighriskpatientsiswelltoleratedandleadstodurableresponses |